Insmed Incorporated (LON:0JAV)

Market Cap	9.89B
Revenue (ttm)	290.52M
Net Income (ttm)	-729.89M
Shares Out	n/a
EPS (ttm)	-4.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	174
Average Volume	176
Open	67.23
Previous Close	69.00
Day's Range	67.23 - 69.68
52-Week Range	16.59 - 71.75
Beta	1.07
RSI	53.03
Earnings Date	May 8, 2025

About Insmed

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 c...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1988
• Employees: 1,271
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0JAV

Financial Performance

In 2024, Insmed's revenue was $363.71 million, an increase of 19.17% compared to the previous year's $305.21 million. Losses were -$913.77 million, 21.9% more than in 2023.

Financial numbers in USD